The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
Open accessAbstract
BACKGROUND: Unresectable locally advanced or metastatic triple-negative (hormone-receptor-negative and human epidermal growth factor receptor 2 [HER2]-negative) breast cancer is an aggressive disease with poor outcomes. Nanoparticle albumin-bound (nab)-paclitaxel may enhance the anticancer activity of atezolizumab. METHODS: In this phase 3 trial, we randomly assigned (in a 1:1 ratio) patients with untreated metastatic triple-negative breast cancer to receive atezolizumab plus nab-paclitaxel or placebo plus nab-paclitaxel; patients continued the intervention until disease progression or an unacceptable level of toxic effects occurred. Stratification factors were the receipt or nonreceipt of neoadjuvant or adjuvant taxane therapy, the presence or absence of liver metastases at baseline, and programmed death ligand 1 (PD-L1) expression at baseline (positive vs. negative). The two primary end points were progression-free survival (in the intention-to-treat population and PD-L1-positive subgroup) and overall survival (tested in the intention-to-treat population; if the finding was significant, then it would be tested in the PD-L1-positive subgroup). RESULTS: Each group included 451 patients (median follow-up, 12.9 months). In the intention-to-treat analysis, the median progression-free survival was 7.2 months with atezolizumab plus nab-paclitaxel, as compared with 5.5 months with placebo plus nab-paclitaxel (hazard ratio for progression or death, 0.80; 95% confidence interval [CI], 0.69 to 0.92; P=0.002); among patients with PD-L1-positive tumors, the median progression-free survival was 7.5 months and 5.0 months, respectively (hazard ratio, 0.62; 95% CI, 0.49 to 0.78; P<0.001). In the intention-to-treat analysis, the median overall survival was 21.3 months with atezolizumab plus nab-paclitaxel and 17.6 months with placebo plus nab-paclitaxel (hazard ratio for death, 0.84; 95% CI, 0.69 to 1.02; P=0.08); among patients with PD-L1-positive tumors, the median overall survival was 25.0 months and 15.5 months, respectively (hazard ratio, 0.62; 95% CI, 0.45 to 0.86). No new adverse effects were identified. Adverse events that led to the discontinuation of any agent occurred in 15.9% of the patients who received atezolizumab plus nab-paclitaxel and in 8.2% of those who received placebo plus nab-paclitaxel. CONCLUSIONS: Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and the PD-L1-positive subgroup. Adverse events were consistent with the known safety profiles of each agent. (Funded by F. Hoffmann-La Roche/Genentech; IMpassion130 ClinicalTrials.gov number, NCT02425891 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, PD-L1 status by SP142 is the companion test for the use of atezolizumab in combination with a taxane for first-line therapy in triple-negative ABC, with a cut-off of 1% positive staining on immune cells.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“an analysis was conducted and presented, and showed an OS of 25 months versus 15.1 months favouring the atezolizumab arm.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [68]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the PD-L1 positive group, atezolizumab provided a PFS benefit of 7.5 versus 5 months with a HR of 0.62 (95% CI 0.49-0.78, P < 0.001).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [68]
The cited source says what the claim attributes to it.
In the citing paper
“In the ITT population, atezolizumab provided a benefit in PFS of 7.2 versus 5.5 months with a HR of 0.8 (95% CI 0.69-0.92, P = 0.002).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [68]
The cited source says what the claim attributes to it.
In the citing paper
“In the ITT population, there was no significant benefit in OS with the addition of atezolizumab; median OS was 21.3 months versus 17.6 months (HR 0.84; 95% CI 0.69-1.02, P = 0.08).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [68]
In the citing paper
“to date, atezolizumab, in combination with chemotherapy, has been approved by the FDA for the treatment of squamous and nonsquamous NSCLC, small cell lung cancer, and PD-L1-positive triple-negative breast cancer (66)(67)(68)(69).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+ · Cited by 16,760
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Hammond, M. E., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G. D., Goldstein, N. S., Hayes, M. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,217
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,080
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F. M., Poortmans, P. M., Rutgers, E. J. T., Zackrisson, S., & Cardoso, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv298 · Cited by 1,660
Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Eenoo, F. V., Rouas, G., Francis, P. A., Crown, J. P., Hitre, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0902 · Cited by 1,658
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Adams S Diamond JR Hamilton E et al. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial. JAMA Oncol (in press).
Cited by
Sorted by citations
Items 801–900 of 1,010
Iivanainen, S., Ekström, J., Virtanen, H., Kataja, V. V., & Koivunen, J. P. (2021) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-021-01564-0 · Cited by 55
Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis
Caparica, R., Bruzzone, M., Agostinetto, E., Angelis, C. D., Fêde, Â., Ceppi, M., & de Azambuja, E. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100066 · Cited by 52
Immunomodulatory effects of G-CSF in cancer: Therapeutic implications
Mouchemore, K. A., & Anderson, R. L. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101512 · Cited by 58
Immune checkpoint inhibitors for the treatment of melanoma
Sabbatino, F., Liguori, L., Pepe, S., & Ferrone, S. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2038132 · Cited by 56
Liposomes-enabled cancer chemoimmunotherapy
Zhang, L., Shi, J., Zhu, M., Huang, Y., Lu, Q., Sun, P., Chen, H., Lai, X. P., & Fang, C. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122801 · Cited by 53
PD-L1/PD-1 axis as a potent therapeutic target in breast cancer
Bastaki, S., Irandoust, M., Ahmadi, A., Hojjat‐Farsangi, M., Ambrose, P., Hallaj, S., Edalati, M., Ghalamfarsa, G., Azizi, G., Yousefi, M., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117437 · Cited by 51
Wu, B. Y., & Ma, F. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920916000 · Cited by 56
High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas
Mei, P., Freitag, C. E., Wei, L., Zhang, Y., Parwani, A. V., & Li, Z. (2020) · Diagnostic Pathology · doi:10.1186/s13000-020-00971-7 · Cited by 55
Larsson, C., Ehinger, A., Winslow, S., Leandersson, K., Klintman, M., Dahl, L., Vallon‐Christersson, J., Häkkinen, J., Hegardt, C., Manjer, J., et al. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-0170-2 · Cited by 52
Update on systemic treatment for newly diagnosed inflammatory breast cancer
Chainitikun, S., Saleem, S., Lim, B., Valero, V., & Ueno, N. T. (2020) · Journal of Advanced Research · doi:10.1016/j.jare.2020.08.014 · Cited by 53
Biomarkers for Response to Immune Checkpoint Blockade
Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033604 · Cited by 51
Tissue-resident memory CD8+ T cells in cancer immunology and immunotherapy
Wang, T., Shen, Y., Luyten, S., Yang, Y., & Jiang, X. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104876 · Cited by 53
Xu, B., Sun, T., Zhang, Q., Zhang, P., Yuan, Z., Jiang, Z., Wang, X., Cui, S., Teng, Y., Hu, X., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.600 · Cited by 50
Sun, S., Zhou, W., Li, X., Peng, F., Yan, M., Zhan, Y., An, F., Li, X., Liu, Y., Liu, Q., et al. (2021) · 癌症：英文版 · doi:10.1002/cac2.12190 · Cited by 51
Torres, E. T. R., & Emens, L. A. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06423-0 · Cited by 51
Self-citationNeoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease
Mittendorf, E. A., Burgers, F. H., Haanen, J. B. A. G., & Cascone, T. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349411 · Cited by 54
Mao, M., Chen, Y., Yang, J., Cheng, Y., Xu, L., Ji, F., Zhou, J., Zhang, X., Li, Z., Chen, C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005668 · Cited by 51
Mekky, R. Y., Ragab, M. F., Manie, T., Attia, A. A., & Youness, R. A. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101653 · Cited by 51
“treat TNBC patients, was the first to show that immune checkpoint inhibitors benefit might be achieved in treating BC patients [5].”
BackgroundCarter, J. M., Chumsri, S., Hinerfeld, D. A., Ma, Y., Wang, X., Zahrieh, D., Hillman, D. W., Tenner, K., Kachergus, J. M., Brauer, H. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37806-0 · Cited by 52
Exosomal long non-coding RNAs in cancer: Interplay, modulation, and therapeutic avenues
Marima, R. M., Basera, A., Miya, T. V., Damane, B. P., Kandhavelu, J., Mirza, S., Penny, C. B., & Dlamini, Z. (2024) · Non-coding RNA Research · doi:10.1016/j.ncrna.2024.03.014 · Cited by 53
“Blocking the activity of exosomal lncRNA-mediated ligand/receptor (PD-1/PD-L1) interaction by immune checkpoint inhibitors may be key in enhancing anti-tumor immunity [156].”
BackgroundAguilera, J. V., Paludo, J., McWilliams, R. R., Zhang, H., Li, Y., Kumar, A. B., Failing, J. J., Kottschade, L. A., Block, M. S., Markovic, S. N., et al. (2020) · Melanoma Research · doi:10.1097/cmr.0000000000000669 · Cited by 51
Horimoto, Y., Hlaing, M. T., Saeki, H., Kitano, S., Nakai, K., Sasaki, R., Kurisaki‐Arakawa, A., Arakawa, A., Otsuji, N., Matsuoka, S., et al. (2020) · Cancer Science · doi:10.1111/cas.14500 · Cited by 51
Jacot, W., Mazel, M., Mollévi, C., Pouderoux, S., D’Hondt, V., Cayrefourcq, L., Bourgier, C., Boissière‐Michot, F., Berrabah, F., Lopez‐Crapez, E., et al. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa121 · Cited by 52
Xin, Y., Shen, G., Zheng, Y., Guan, Y., Huo, X., Li, J., Ren, D., Zhao, F., Liu, Z., Li, Z., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08997-w · Cited by 53
Nanoparticles: Promising Tools for the Treatment and Prevention of Myocardial Infarction
Pan, Q., Xu, J., Wen, C.-J., Xiong, Y., Gong, Z., & Yang, Y. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s328723 · Cited by 53
Arellano, D. L., Juárez, P., Verdugo‐Meza, A., Almeida‐Luna, P. S., Corral‐Avila, J. A., Drescher, F., Olvera, F., Jiménez, S., Elzey, B. D., Guise, T. A., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4615 · Cited by 53
Zhao, Q. S., He, X., Qin, X., Liu, Y., Jiang, H., Wang, J., Wu, S., Zhou, R., Yu, C., Liu, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.938439 · Cited by 51
“Mice bearing tumors were distributed into six groups (1) Saline (control), (2) a-PD1 (3) Losartan + a-PD1, (4) Losartan + Dox-L, (5) Dox-L + aPD1, (6) Losartan + Dox-L + a-PD1, the treatment schedule is described in Figure 2A.”
BackgroundMethodInfluentialZhao, H., Liang, Y., Sun, C., Zhai, Y., Li, X., Jiang, M., Yang, R., Li, X., Shu, Q., Kai, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315180 · Cited by 50
“Although anthracycline and taxane-based drugs can improve life quality and survival time in the early stages, no effective treatment is available for TNBC patients [3,4].”
BackgroundTumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities
Barroso‐Sousa, R., Pacifico, J. P. M., Sammons, S. L., & Tolaney, S. M. (2023) · Cancers · doi:10.3390/cancers15153997 · Cited by 54
“In the IMpassion130 study [5], atezolizumab combined with nab-paclitaxel showed improved PFS and clinically meaningful OS benefit versus placebo combined with nabpaclitaxel for patients with mTNBC with PD-L1 ≥ 1% expression on tumor-infiltrating immune cells.”
Wei, J., Lu, X., Liu, Q., Fu, Y. S., Liu, S., Zhao, Y., Zhou, J., Chen, H., Wang, M., Li, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40480-x · Cited by 52
Sharma, P., Barlow, W. E., Godwin, A. K., Parkes, E. E., Knight, L. A., Walker, S. M., Kennedy, R. D., Harkin, D. P., Logan, G. E., Steele, C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00693 · Cited by 49
McGuinness, J. E., & Kalinsky, K. M. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1840547 · Cited by 52
Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer
Freelander, A., Brown, L. J., Parker, A. J., Segara, D., Portman, N., Lau, B., & Lim, E. (2021) · Genes · doi:10.3390/genes12020285 · Cited by 52
Tumor-intrinsic determinants of immunogenic cell death modalities
Workenhe, S. T., Pol, J. G., & Kroemer, G. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1893466 · Cited by 52
Pharmacogenomics in the era of next generation sequencing – from byte to bedside
Russell, L. E., Zhou, Y., Almousa, A. A., Sodhi, J. K., Nwabufo, C. K., & Lauschke, V. M. (2021) · Drug Metabolism Reviews · doi:10.1080/03602532.2021.1909613 · Cited by 52
Biomaterials‐Based Delivery of Therapeutic Antibodies for Cancer Therapy
Ye, Q., Wang, Y., Shen, S., Xu, C., & Wang, J. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002139 · Cited by 50
Morimoto, K., Uchino, J., Yokoi, T., Kijima, T., Gotô, Y., Nakao, A., Hibino, M., Takeda, T., Yamaguchi, H., Takumi, C., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1950411 · Cited by 49
Predictive biomarkers for personalized medicine in breast cancer
Rodrigues-Ferreira, S., & Nahmias, C. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215828 · Cited by 50
Intratumoral hypoxia and mechanisms of immune evasion mediated by hypoxia-inducible factors
Semenza, G. L. (2021) · Physiology · doi:10.1152/physiol.00034.2020 · Cited by 64
Targeting triple-negative breast cancers with the Smac-mimetic birinapant
Lalaoui, N., Merino, D., Giner, G., Vaillant, F., Chau, D., Liu, L., Kratina, T., Pal, B., Whittle, J. R., Etemadi, N., et al. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-020-0541-0 · Cited by 51
Ünal, T., Hamurcu, Z., Delibaşı, N., Çınar, V., Güler, A., Gökçe, S., Nurdinov, N. S., & Ozpolat, B. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200807221047 · Cited by 49
MHC Class I Loss in Triple-negative Breast Cancer
Dusenbery, A. C., Maniaci, J. L., Hillerson, N. D., Dill, E. A., Bullock, T. N. J., & Mills, A. M. (2021) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001653 · Cited by 49
Li, Z.-C., Sun, Y., Lai, M.-Y., Zhou, Y.-X., & Qiu, M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108790 · Cited by 50
Mamot, C., WICKI, A. N., Hasler-Strub, U., Riniker, S., Li, Q., Holer, L., Bärtschi, D., Zaman, K., von Moos, R., Dedes, K. J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-30950-z · Cited by 49
The role of m6A epigenetic modifications in tumor coding and non-coding RNA processing
Wen, T., Li, T., Xu, Y., Zhang, Y., Pan, H., & Wang, Y. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01385-w · Cited by 50
The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC)
Michaels, E., Chen, N., & Nanda, R. (2024) · Clinical Breast Cancer · doi:10.1016/j.clbc.2024.03.001 · Cited by 54
Wu, W., Jing, D., Meng, Z., Hu, B., Zhong, B., Deng, X., Jin, X., & Shao, Z. (2020) · Theranostics · doi:10.7150/thno.41279 · Cited by 50
Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer
Yao, H., Xie, S., Ma, X., Liu, J., Wu, H., Lin, A., Yao, H., Li, D., Xu, S., Yang, D., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00408 · Cited by 49
Lau, D., Garçon, F., Chandra, A., Lechermann, L. M., Aloj, L., Chilvers, E. R., Corrie, P. G., Okkenhaug, K., & Gallagher, F. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01514 · Cited by 51
Workenhe, S. T., Nguyen, A., Bakhshinyan, D., Wei, J., Hare, D. N., MacNeill, K. L., Wan, Y., Oberst, A., Bramson, J. L., Nasir, J. A., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01362-w · Cited by 50
Adoptive Cell Therapy in Breast Cancer: A Current Perspective of Next-Generation Medicine
Fuentes‐Antrás, J., Guevara‐Hoyer, K., Baliu‐Piqué, M., García-Sáenz, J. Á., Pérez‐Segura, P., Pandiella, A., & Ocaña, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.605633 · Cited by 49
Parvathareddy, S. K., Siraj, A. K., Al-Badawi, I. A., Tulbah, A. M., Al‐Dayel, F., & Al-Kuraya, K. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-83276-z · Cited by 55
Unraveling Immune-Related lncRNAs in Breast Cancer Molecular Subtypes
Mathias, C., Muzzi, J. C. D., Antunes, B. B., Gradia, D. F., Castro, M. A. A., & de Oliveira, J. C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.692170 · Cited by 49
Charting roadmaps towards novel and safe synergistic immunotherapy combinations
Sanmamed, M. F., Berraondo, P., Rodriguez-Ruiz, M. E., & Melero, I. (2022) · Nature Cancer · doi:10.1038/s43018-022-00401-1 · Cited by 50
Keenan, T. E., Guerriero, J. L., Barroso‐Sousa, R., Li, T., O’Meara, T. A., Giobbie‐Hurder, A., Tayob, N., Hu, J., Severgnini, M., Agudo, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25769-z · Cited by 49
Self-citationKulasinghe, A., Monkman, J. H., Shah, E. T., Matigian, N., Adams, M. N., & O'Byrne, K. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.798296 · Cited by 48
“Furthermore, PD-L1 positive disease displayed improved OS in response to anti-PD-L1 immunotherapy in phase III IMpassion130 trial (41), and has subsequently shown improved outcome in response to combination therapies (18).”
BackgroundApplications of Artificial Intelligence in Breast Pathology
Liu, Y., Han, D., Parwani, A. V., & Li, Z. (2023) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2022-0457-ra · Cited by 55
Wu, S., Zhang, S.-W., Ma, D., Xiao, Y. Q., Liu, Y., Chen, L., Song, X.-Q., Ma, X.-Y., Xu, Y., Chai, W.-J., et al. (2023) · Med · doi:10.1016/j.medj.2023.04.008 · Cited by 49
Ge, L., Jin, X., Ma, D., Wang, Z.-Y., Liu, C., Zhou, C., Zhao, S., Yu, T., Liu, X., Di, G. H., et al. (2024) · Cell Research · doi:10.1038/s41422-023-00909-w · Cited by 51
Noske, A., Möbus, V. J., Weber, K. E., Schmatloch, S., Weichert, W., Köhne, C., Solbach, C., Heppner, B. I., Steiger, K., Müller, V., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.010 · Cited by 48
Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer
Nakhjavani, M., Hardingham, J. E., Palethorpe, H. M., Price, T. J., & Townsend, A. R. (2019) · Journal of Breast Cancer · doi:10.4048/jbc.2019.22.e39 · Cited by 49
Low doses in immunotherapy: Are they effective?
Prabhash, K., Patil, V. M., Noronha, V., Joshi, A. D., Abhyankar, A. V., Menon, N. S., Banavali, S. D., & Gupta, S. (2019) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_29_19 · Cited by 48
Hammerl, D., Massink, M. P. G., Smid, M., van Deurzen, C. H. M., Meijers-Heijboer, H. E. J., Waisfisz, Q., Debets, R., & Martens, J. W. M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0285 · Cited by 46
Choi, J. W., Withers, S. S., Chang, H., Spanier, J. A., Trinidad, V. L. D. L., Panesar, H. K., Fife, B. T., Sciammas, R., Sparger, E. E., Moore, P. F., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235518 · Cited by 53
Kyte, J. A., Andresen, N. K., Russnes, H., Fretland, S. Ø., Falk, R. S., Lingjærde, O. C., & Naume, B. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02421-w · Cited by 48
Zhang, J., Wang, L., Xu, X., Li, X., Guan, W., Meng, T., & Xu, G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01787 · Cited by 46
Draganov, D., Han, Z., Rana, A., Bennett, N. R., Irvine, D. J., & Lee, P. P. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00229-5 · Cited by 49
Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches
Pellerino, A., Brastianos, P. K., Rudà, R., & Soffietti, R. (2021) · Cancers · doi:10.3390/cancers13122888 · Cited by 48
Breast Cancer CAFs: Spectrum of Phenotypes and Promising Targeting Avenues
Elwakeel, E., & Weigert, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111636 · Cited by 49
BIRC2 Expression Impairs Anti-Cancer Immunity and Immunotherapy Efficacy
Samanta, D., Huang, T. Y.-T., Shah, R., Yang, Y., Pan, F., & Semenza, G. L. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108073 · Cited by 49
Triple-negative breast cancer: new treatment strategies in the era of precision medicine
Wu, S., Wang, H., Shao, Z., & Jiang, Y. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1714-8 · Cited by 50
Immunotherapy in triple-negative breast cancer: A literature review and new advances
Valencia, G., Rioja, P., Morante, Z., Ruiz, R., Fuentes, H. A., Castañeda, C. A., Vidaurre, T., Neciosup, S. P., & Gómez, H. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i3.219 · Cited by 48
Rizvi, N. A., Ademuyiwa, F. O., Cao, Z. A., Chen, H. X., Ferris, R. L., Goldberg, S. B., Hellmann, M. D., Mehra, R., Rhee, I. P., Park, J. C., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005920 · Cited by 52
Reinforcing the immunogenic cell death to enhance cancer immunotherapy efficacy
Yu, S., Xiao, H., Ma, L., Zhang, J., & Zhang, J. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188946 · Cited by 47
The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments
Rayson, V., Harris, M. A., Savas, P. S., Hun, M. L., Virassamy, B., Salgado, R., & Loi, S. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.02.008 · Cited by 49
Self-citationColomer, R., González‐Farré, B., Ballesteros, A. I., Peg, V., Bermejo, B., Perez‐Mies, B., de la Cruz, S., Rojo, F., Pernas, S., & Palacios, J. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03541-1 · Cited by 55
Intratumoral Injection of Immunotherapeutics: State of the Art and Future Directions
Sheth, R. A., Wehrenberg-Klee, E. P., Patel, S. P., Brock, K. K., Fotiadis, N., & de Baère, T. (2024) · Radiology · doi:10.1148/radiol.232654 · Cited by 51
Correlation Analysis of Histopathology and Proteogenomics Data for Breast Cancer
Zhan, X., Cheng, J., Huang, Z., Han, Z., Helm, B. R., Liu, X., Zhang, J., Wang, T., Ni, D., & Huang, K. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.001232 · Cited by 48
Zhou, Z.-Q., Zhao, J.-J., Pan, Q., Chen, C.-L., Liu, Y., Tang, Y., Zhu, Q., Weng, D., & Xia, J. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0696-8 · Cited by 47
Nederlof, I., Bortoli, D. D., Barèche, Y., Nguyen, B., de Maaker, M., Hooijer, G. K. J., Buisseret, L., Kok, M., Smid, M., den Eynden, G. G. G. M. V., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1239-4 · Cited by 46
Medical management of brain metastases
Lauko, A. J., Rauf, Y., & Ahluwalia, M. S. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa015 · Cited by 51
Danesi, R., Fogli, S., Indraccolo, S., Re, M. D., Tos, A. P. D., Leoncini, L., Antonuzzo, L., Bonanno, L., Guarneri, V., Pierini, A., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100040 · Cited by 52
Emerging Therapeutics for Patients with Triple-Negative Breast Cancer
Agostinetto, E., Eiger, D., Punie, K., & de Azambuja, E. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01038-6 · Cited by 47
Bai, X., Ni, J., Beretov, J., Graham, P., & Li, Y. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2021.06.001 · Cited by 50
Iwata, H., Inoue, K., Kaneko, K., Ito, Y., Tsugawa, K., Hasegawa, A., Nakagawa, S., Kuratomi, H., & Tamura, K. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz135 · Cited by 46
Self-citationOshi, M., Newman, S., Murthy, V., Tokumaru, Y., Yan, L., Matsuyama, R., Endo, I., & Takabe, K. (2020) · Cancers · doi:10.3390/cancers12102758 · Cited by 46
Williams, M. M., Christenson, J. L., O’Neill, K. I., Hafeez, S. A., Ihle, C. L., Spoelstra, N. S., Slansky, J. E., & Richer, J. K. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00273-1 · Cited by 46
Cancer Immunotherapy and Delivery System: An Update
Yang, M. J., Olaoba, O. T., Zhang, C., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081630 · Cited by 46
Erasha, A. M., El-Gendy, H. F., Aly, A. S., Fernández‐Ortiz, M., & Sayed, R. K. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062716 · Cited by 52
“In advanced triple-negative breast cancer (TNBC) patients, the anti-PD-L1 drug atezolizumab has significantly reduced PD-L1-positive (PD-L1+) metastases and increased overall sur-Int vival [78].”
Signorelli, D., Giannatempo, P., Grazia, G., Aiello, M. M., Bertolini, F., Mirabile, A., Buti, S., Vasile, E., Scotti, V., Pisapia, P., et al. (2019) · BioMed Research International · doi:10.1155/2019/9056417 · Cited by 47
Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker
Fountzilas, E., Kurzrock, R., Vo, H. H., & Tsimberidou, A. M. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab067 · Cited by 44
CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer
Hlevnjak, M., Schulze, M., Elgaafary, S., Fremd, C., Michel, L. L., Beck, K., Pfütze, K., Richter, D., Wolf, S., Horak, P., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00248 · Cited by 47
Li, Z., & Rong, L. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c04305 · Cited by 46
Prognostic and Clinicopathologic Associations of LAG-3 Expression in Triple-negative Breast Cancer
Stovgaard, E. S., Kümler, I., List-jensen, K., Roslind, A., Christensen, I. J., Høgdall, E. V. S., Nielsen, D., & Balslev, E. (2021) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000954 · Cited by 46
Barroso‐Sousa, R., Keenan, T. E., Li, T., Tayob, N., Trippa, L., Pastorello, R., Richardson, E. T., Dillon, D. A. R., Amoozgar, Z., Overmoyer, B. A., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00287-9 · Cited by 46
Self-citationLiu, Z., Wang, C., Chen, X., Zhu, J., Sun, X., Xia, Q., Lu, Z., Qiao, J., Zhou, Y. C., Wang, H., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.01.022 · Cited by 46
Kattan, J. G., Kattan, C., & Assi, T. (2020) · Immunotherapy · doi:10.2217/imt-2020-0077 · Cited by 45
How current assay approval policies are leading to unintended imprecision medicine
Salgado, R., Bellizzi, A. M., Rimm, D. L., Bartlett, J. M. S., Nielsen, T. O., Moch, H., Lænkholm, A., Quinn, C., Cserni, G., da Cunha, I. W., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30592-1 · Cited by 45
MicroRNA Expression Profiles and Breast Cancer Chemotherapy
Davey, M. G., Lowery, A., Miller, N., & Kerin, M. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910812 · Cited by 45
Frailty and checkpoint inhibitor toxicity in older patients with melanoma
Bruijnen, C. P., Koldenhof, J. J., Verheijden, R. J., van den Bos, F., Emmelot‐Vonk, M. H., Witteveen, P. O., & Suijkerbuijk, K. P. M. (2022) · Cancer · doi:10.1002/cncr.34230 · Cited by 48
Metadata
- Authors
- Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., Henschel, V., Molinero, L., Chui, S. Y., Funke, R., Husain, A., Winer, E. P., Loi, S., & Emens, L. A.
- Affiliations
- Queen Mary University of London (GB)
- From the Barts Cancer Institute, Queen Mary University of London, London (P.S.); Perlmutter Cancer Center, New York University School of Medicine, New York (S.A.); the Department of Medicine, University of California, San Francisco, San Francisco (H.S.R.), and Genentech, South San Francisco (L.M., S.Y.C., R.F.) — both in California; University Hospital Heidelberg, Heidelberg, Germany (A.S.); Centro de Pesquisa em Oncologia, Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul,...
- Seoul National University (KR)
- F. Hoffmann-La Roche AG (CH)
- The University of Melbourne (AU)
- Johns Hopkins University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2108-2121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2897422388
- Cited by
- 4,350
- References
- 32
- Citations by year
- 2026: 310 · 2025: 409 · 2024: 453 · 2023: 562 · 2022: 648 · 2021: 825 · 2020: 723 · 2019: 397 · 2018: 17
- FWCI
- 148.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- F. Hoffmann-La Roche/Genentech
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- atezolizumab, nab-paclitaxel, triple-negative breast cancer, metastatic breast cancer, PD-L1 expression, immune checkpoint inhibitors, combination chemotherapy, progression-free survival, overall survival, liver metastasis, immune-related adverse events, PD-1/PD-L1 inhibitors
- MeSH terms
- Progression-Free Survival, Adult, Aged, Albumins, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Middle Aged, Survival Analysis, Paclitaxel, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
